Compare Sezzle Inc (SEZL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs TransMedics Group Inc — how do they compare? Sezzle Inc trades at $118.51 (market cap $3.99B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Sezzle Inc is the larger of the two by market cap, and Sezzle Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SEZL | TMDX | |
|---|---|---|
Market Cap | $3.99B | $3.06B |
Sector | Technology | Technology |
52-Week High | $188.55 | $150.42 |
52-Week Low | $50.97 | $61.99 |
Enterprise Value | $4.03B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEZL trades at $118.35, down 1.85% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 30.35% net income margin and consistent earnings beats in recent quarters. Recent business developments include merchant network expansion with Gymshark and Debenhams Group, while analyst consensus remains bullish with a $161.17 price target representing 36% upside potential.
SEZL presents a compelling growth story with robust profitability metrics and expanding market presence, though technical weakness and high valuation multiples warrant caution. The stock offers significant upside based on analyst targets but faces execution risks in competitive fintech landscape and potential market volatility.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
